CYP2D6

細胞色素 P450 2D6（cytochrome P450 2D6，CYP2D6）是一種由人類CYP2D6基因編碼的酶。CYP2D6主要合成而顯現於肝臟，並且也表現在中樞神經系統中，包括黑質。

Cytochrome P450, family 2, subfamily D, polypeptide 6
PDB基於2f9q的渲染圖
有效結構 PDB 直系同源檢索：PDBe, RCSB PDB查詢代碼列表 2F9Q, 3QM4, 3TBG, 3TDA, 4WNT, 4WNU, 4WNV, 4WNW
標識
代號	CYP2D6; CPD6; CYP2D; CYP2D7AP; CYP2D7BP; CYP2D7P2; CYP2D8P2; CYP2DL1; CYPIID6; P450-DB1; P450C2D; P450DB1
擴展標識	遺傳學：124030 鼠基因：1929474 同源基因：133550 GeneCards: CYP2D6 Gene
EC編號	1.14.14.1
基因本體論描述 分子功能 · monooxygenase activity · iron ion binding · drug binding · arachidonic acid epoxygenase activity · steroid hydroxylase activity · oxidoreductase activity · oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen · oxygen binding · heme binding · aromatase activity 細胞成分 · cytoplasm · mitochondrion · endoplasmic reticulum · endoplasmic reticulum membrane 生物過程 · xenobiotic metabolic process · steroid metabolic process · coumarin metabolic process · alkaloid metabolic process · alkaloid catabolic process · monoterpenoid metabolic process · drug metabolic process · arachidonic acid metabolic process · isoquinoline alkaloid metabolic process · drug catabolic process · exogenous drug catabolic process · small molecule metabolic process · heterocycle metabolic process · negative regulation of binding · oxidation-reduction process · oxidative demethylation · negative regulation of cellular organofluorine metabolic process Sources: Amigo / QuickGO
RNA表達模式
更多表達數據
直系同源體
物種	人類	小鼠
Entrez	1565	13101
Ensembl	ENSG00000100197	ENSMUSG00000094806
UniProt	P10635	P24456
mRNA序列	NM_000106	NM_010005
蛋白序列	NP_000097	NP_034135
基因位置	Chr 22: 42.13 – 42.13 Mb	Chr 15: 82.4 – 82.41 Mb
PubMed查詢	[1]	[2]
閱 論 編

CYP2D6是細胞色素P450混合功能氧化酶系統的成員之一，是人體中最重要的代謝酶之一。CYP2D6參與25%的臨床藥物的代謝和清除，過程主要是O-去甲基化。^[1]CYP2D6也參與多種內源性物質的代謝，如5-羥色胺和神經類固醇。^[1]

引用

1. Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab. Rev. 2009, 41 (4): 573–643. PMID 19645588. doi:10.1080/03602530903118729.

延伸閱讀

• Smith G, Stubbins MJ, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica. 1998, 28 (12): 1129–65. PMID 9890157. doi:10.1080/004982598238868.
• Wolf CR, Smith G. Cytochrome P450 CYP2D6. IARC Sci. Publ. 1999, (148): 209–29. PMID 10493260.
• Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 2003, 43 (1): 149–73. PMID 12171978. doi:10.1146/annurev.pharmtox.43.100901.140251.
• Lilienfeld S. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002, 8 (2): 159–76. PMID 12177686. doi:10.1111/j.1527-3458.2002.tb00221.x.
• Yu AM, Idle JR, Gonzalez FJ. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab. Rev. 2004, 36 (2): 243–77. PMID 15237854. doi:10.1081/DMR-120034000.
• Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, Luccarini C, Shah M, Ingle S, Greenberg D, Earl HM, Dunning AM, Pharoah PD, Caldas C. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res. 2010, 12 (4): R64. PMC 2949659 . PMID 20731819. doi:10.1186/bcr2629.
• Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, Luccarini C, Earl HM, Dunning AM, Pharoah PD, Caldas C. CYP2D6 gene variants and their association with breast cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 2011, 20 (6): 1255–8. PMID 21527579. doi:10.1158/1055-9965.EPI-11-0321.

外部連結

• Flockhart Lab Cyp2D6 Substrates Page（頁面存檔備份，存於互聯網檔案館） at IUPUI
• PharmGKB: Annotated PGx Gene Information for CYP2D6